ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

Also in this 8-page issue: FISH assay predicts survival on Iressa, Univ. of Colorado Cancer Center study finds.

May 6, 2005

Murray Copeland Display Dedicated

March 18, 1983

Mandates Not welcome In Steady State Funding, Varmus Tells Senate

March 15, 1996

FDA Proposal On Dissemination of Off-Label Drug Information Doesn’t Go Far Enough, Cancer Groups Say

January 26, 1996

USC $2.5 Million contract Tops Last Minute FY 75 Rush of Awards

July 18, 1975

Rauscher Says He May Leave, But Will Stay Through June

February 6, 1976